<DOC>
	<DOC>NCT01217632</DOC>
	<brief_summary>The overall goal of this trial is to evaluate the efficacy of FG-3019 for reversing liver fibrosis in subjects with chronic hepatitis B infection who are beginning antiviral therapy with entecavir. This Phase 2 randomized, double-blind, placebo controlled study will enroll subjects with chronic active hepatitis B infection and liver fibrosis (Ishak score ≥2) who are eligible for antiviral therapy.</brief_summary>
	<brief_title>A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Signed informed consent Age of 18 to 75 years, inclusive HBsAg positive for ≥24 weeks prior to screening Liver fibrosis, confirmed by biopsy and histology Willing to use contraception Female subjects who are pregnant or nursing Prior antiviral therapy, with the exception of interferon therapy &gt;6 months prior to Day 1 Severe heart failure Present hepatocellular carcinoma and history of other cancers Severe anemia Advanced kidney disease Immunosuppressive therapy within 24 weeks prior to screening Alcohol or drug abuse within the 12 months prior to screening Trauma or surgical procedures requiring hospitalization within 8 weeks prior to Day 1 Planned elective surgery during the study including 9 weeks following the final dose of study drug History of allergy against nucleoside analogs or human, humanized, chimeric, or murine monoclonal antibodies Inability to cooperate with study personnel or a history of noncompliance to the medical regimen (i.e., subjects who would be expected to comply poorly with the treatment) Clinically significant medical or psychiatric condition considered a high risk for participation in an investigational study Morbid obesity (body mass index [BMI] &gt;40) Inadequate IV access</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Connective tissue growth factor (CTGF)</keyword>
	<keyword>human IgG1 monoclonal antibody</keyword>
</DOC>